AAVL
Of all the issues to pop-up out of the trial, safety isn't on my list. Subretinal injection is fine, little to go wrong with skilled personnel carrying out the vitrectomy.
Agree on the size of Ph2b(or whatever its called) should be on the smaller end of the scale, preferably targeted at a narrower group of patients. No idea on the size of trial contemplated by AAVL, no details release to date, nor if they might now change tack. Seems sensible for them to take a hard look at their plans in light of poor market reaction to 2a data.
Market Data 
Markets 
AI
